First two patients with aggressive forms of adult T-cell leukemia/lymphoma treated with cobomarsen demonstrated greater than five months of clinical response with improvement in objective disease meas...
BOULDER, Colo., May 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapi...
BOULDER, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapi...
MRG-110 advanced into clinical development with the initiation of two Phase 1 clinical trials in collaboration with ServierPreclinical data released in two separate ophthalmology programs targeting mi...
Treatment resulted in durable improved quality of lifeCobomarsen continued to be generally well tolerated at all dose levels evaluatedAdvancing into a Phase 2 clinical trial in second half of 2018BOUL...
